Effects of burosumab on osteocalcin and bone mineral density in patient with 15-year history of nonremission tumor-induced osteomalacia initially treated with conventional therapy: Case report

Excess fibroblast growth factor 23 (FGF23) causes hypophosphatemic osteomalacia, which is associated with impaired bone matrix mineralization. Tumor-induced osteomalacia (TIO) is a rare paraneoplastic syndrome caused by over-secretion of FGF23 from a tumor. Burosumab, a fully human monoclonal antibo...

Descripción completa

Detalles Bibliográficos
Autores principales: Miyaoka, Daichi, Imanishi, Yasuo, Yano, Masahiro, Toi, Norikazu, Nagata, Yuki, Kurajoh, Masafumi, Yamada, Shinsuke, Morioka, Tomoaki, Emoto, Masanori
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7701316/
https://www.ncbi.nlm.nih.gov/pubmed/33294501
http://dx.doi.org/10.1016/j.bonr.2020.100736

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7701316/
https://www.ncbi.nlm.nih.gov/pubmed/33294501
http://dx.doi.org/10.1016/j.bonr.2020.100736

Ejemplares similares